Boston Scientific Corporation vs Spotify Technology — how do they compare? Boston Scientific Corporation trades at $42.73 (market cap $66.37B), while Spotify Technology trades at $481.83 (market cap $98.92B). The key difference: Spotify Technology is the larger of the two by market cap, and Spotify Technology is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | SPOT | |
|---|---|---|
Market Cap | $66.37B | $98.92B |
Sector | Health | Media |
52-Week High | $108.14 | $738.53 |
52-Week Low | $42.63 | $412.75 |
Enterprise Value | $75.94B | $89.50B |
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Spotify (SPOT) trades at $479.84, showing minimal daily movement (+0.01%) amid neutral technical signals. The company demonstrates strong fundamental momentum with revenue growing from $11.7B in 2022 to $17.2B in 2025, while achieving profitability turnaround from losses to $2.2B net income. Recent earnings beats and AI integration initiatives highlight operational strength, though technical indicators show mixed signals with bearish moving averages and neutral oscillators.
Spotify presents a compelling growth story with accelerating profitability and analyst optimism (61.5% buy ratings), though faces execution risks in competitive streaming markets. The stock trades at a premium valuation (P/E 32.7) but offers 28% upside to consensus target of $617. Key risks include market saturation and royalty cost pressures, while AI innovation provides growth catalysts.
Trailing returns across standard periods
Latest headlines on both assets
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →